Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ranitidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH2 known ✓ | P25021 | 1/20 | 0.96 |
| ▸ | ACHE | P22303 | 15/20 | 0.96 |
| ▸ | MEN1 | O00255 | 1/20 | 0.96 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.96 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.96 |
| ▸ | LMNA | P02545 | 1/20 | 0.96 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.96 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.96 |
| ▸ | TSHR | P16473 | 1/20 | 0.96 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.96 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.96 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.96 |
| ▸ | ATP4A | P20648 | 1/20 | 0.96 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.96 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.96 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.96 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.96 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.96 |
| ▸ | ATP4B | P51164 | 1/20 | 0.96 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.96 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ranitidine SCHEMBL2228178 | 0.98 | RAD52 (0.98) | ACHEMEN1SLC22A1ABCB11LMNA | |
| Ranitidine SCHEMBL33300 | 0.98 | ACHE (0.96) | ACHEMEN1SLC22A1ABCB11LMNA | |
| Ranitidine SCHEMBL826 | 0.98 | ACHE (1.00) | ACHEMEN1SLC22A1ABCB11LMNA | |
| Ranitidine SCHEMBL8796367 | 0.98 | ACHE (1.00) | ACHEMEN1SLC22A1ABCB11LMNA | |
| Ranitidine SCHEMBL824 | 0.98 | ACHE (1.00) | ACHEMEN1SLC22A1ABCB11LMNA | |
| Ranitidine SCHEMBL825 | 0.98 | ACHE (1.00) | ACHEMEN1SLC22A1ABCB11LMNA | |
| Ranitidine SCHEMBL8594797 | 0.98 | ACHE (1.00) | ACHEMEN1SLC22A1ABCB11LMNA | |
| Ranitidine SCHEMBL1536277 | 0.97 | ACHE (0.98) | ACHEMEN1SLC22A1ABCB11LMNA | |
| Ranitidine SCHEMBL8110889 | 0.97 | RAD52 (1.00) | ACHEMEN1SLC22A1ABCB11LMNA | |
| Ranitidine SCHEMBL33298 | 0.97 | RAD52 (1.00) | ACHEMEN1SLC22A1ABCB11LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2279682-A | — | — | None | — | — | JP | disclosed |
| US-9533056-B2 | Dipeptide-based prodrug linkers for aliphatic amine-containing drugs | ASCENDIS PHARMA AS (DK) | 2017-01-03 | — | — | US | disclosed |
| EP-2525830-B1 | DIPEPTIDE-BASED PRODRUG LINKERS FOR ALIPHATIC AMINE-CONTAINING DRUGS | ASCENDIS PHARMA AS (DK) | 2016-05-11 | — | — | EP | disclosed |
| US-20150202317-A1 | DIPEPTIDE-BASED PRODRUG LINKERS FOR ALIPHATIC AMINE-CONTAINING DRUGS | ASCENDIS PHARMA AS (DK) | 2015-07-23 | — | — | US | disclosed |
| US-9062094-B2 | Dipeptide-based prodrug linkers for aliphatic amine-containing drugs | ASCENDIS PHARMA AS (DK) | 2015-06-23 | — | — | US | disclosed |
| US-20130053301-A1 | DIPEPTIDE-BASED PRODRUG LINKERS FOR ALIPHATIC AMINE-CONTAINING DRUGS | ASCENDIS PHARMA A/S (DK) | 2013-02-28 | — | — | US | disclosed |
| WO-2011089216-A1 | DIPEPTIDE-BASED PRODRUG LINKERS FOR ALIPHATIC AMINE-CONTAINING DRUGS | ASCENDIS PHARMA AS (DK) | 2011-07-28 | — | — | WO | disclosed |
| JP-H02279682-A | FURAN DERIVATIVE AND ITS PRODUCTION | LAB VINAS SA | 1990-11-15 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150202317-A1 | DIPEPTIDE-BASED PRODRUG LINKERS FOR ALIPHATIC AMINE-CONTAINING DRUGS | DNPEP, PEPD, DAO | HRH2 1647/4885ACHE 2797/4885MEN1 1118/4885 |
| US-20130053301-A1 | DIPEPTIDE-BASED PRODRUG LINKERS FOR ALIPHATIC AMINE-CONTAINING DRUGS | DNPEP, PEPD, DAO | HRH2 1647/4885ACHE 2797/4885MEN1 1118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.